Xiaojing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaojing Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Guorong Fan
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Xucong Huang
School of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China
3 shared publications- Zhenghua Wu
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Mengqi Jia
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, PR China
2 shared publications- Yanchao Liu
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, PR China
2 shared publications - Yuefen Lou
Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200434, PR China
2 shared publications
Latest Publications
- 16 July 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 220, 114947
Identification of bicyclol metabolites in rat plasma, urine and feces by UPLC-Q-TOF-MS/MS and evaluation of the efficacy and safety of these metabolites based on network pharmacology and molecular docking combined with toxicity prediction
- 16 July 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 220, 114947
Identification of bicyclol metabolites in rat plasma, urine and feces by UPLC-Q-TOF-MS/MS and evaluation of the efficacy and safety of these metabolites based on network pharmacology and molecular docking combined with toxicity prediction
- 25 January 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 289, 115031
Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-β signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification
- 25 January 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 289, 115031
Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-β signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification
- Open Access
- 1 January 2022
- Published by Wiley in Journal of Nanomaterials
- Vol. 2022 (1)
Attenuation of Liver Injury via Bicyclol–Bovine Serum Albumin Nanopreparation using a Green Synthetic Approach
Bicyclol (BIC) is a traditional antihepatitis drug that is used to treat chronic hepatitis B infections by improving liver function and reducing transaminase levels. Because the extensive use of BIC for treating liver injury is limited by its poor bioavailability, the course of treatment with oral BIC lasted for >6 months. This study aimed to develop a nano‐BIC injection to improve its bioavailability and anti‐hepatitis efficacy. We used a green synthetic approach to prepare BIC‐bovine serum albumin (BSA) nanoparticles (BIC‐NPs). Moderate protein denaturation is required to release free thiol groups in the intramolecular reactions of BSA, which may form an intermolecular disulfide network to stabilize the BIC–BSA nanoassembly. Our results showed that the administration of BIC‐NPs in rats resulted in a 2.42‐fold increase in drug concentration in plasma. Further, nano‐BIC injection showed high bioavailability and rapidly achieved therapeutic concentrations. BIC can restore mitochondrial function by scavenging reactive oxygen species. Moreover, we observed that 70 nm NPs can accumulate in the liver, and the nano‐BIC injection protected mice from methotrexate‐induced liver injury. This study provides an improved strategy for developing a liver‐protecting agent to meet various clinical needs of patients.
- 1 January 2022
- Published by Wiley in Journal of Nanomaterials
- Vol. 2022 (1)
Open AccessAttenuation of Liver Injury via Bicyclol–Bovine Serum Albumin Nanopreparation using a Green Synthetic Approach
Bicyclol (BIC) is a traditional antihepatitis drug that is used to treat chronic hepatitis B infections by improving liver function and reducing transaminase levels. Because the extensive use of BIC for treating liver injury is limited by its poor bioavailability, the course of treatment with oral BIC lasted for >6 months. This study aimed to develop a nano‐BIC injection to improve its bioavailability and anti‐hepatitis efficacy. We used a green synthetic approach to prepare BIC‐bovine serum albumin (BSA) nanoparticles (BIC‐NPs). Moderate protein denaturation is required to release free thiol groups in the intramolecular reactions of BSA, which may form an intermolecular disulfide network to stabilize the BIC–BSA nanoassembly. Our results showed that the administration of BIC‐NPs in rats resulted in a 2.42‐fold increase in drug concentration in plasma. Further, nano‐BIC injection showed high bioavailability and rapidly achieved therapeutic concentrations. BIC can restore mitochondrial function by scavenging reactive oxygen species. Moreover, we observed that 70 nm NPs can accumulate in the liver, and the nano‐BIC injection protected mice from methotrexate‐induced liver injury. This study provides an improved strategy for developing a liver‐protecting agent to meet various clinical needs of patients.